drugset
drugset / Trial / NCT06562647

SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors

NCT06562647 ↗

Recruiting 2 enrolled Cell Origin Biotech (Hangzhou) Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Single-arm, dose-increasing setting study of CAR macrophages in Mesothelin overexpressing solid tumors.

Timeline

Start
2023-04-12
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SY001 Unknown 1109 cells Intravenous

Indications

cancer-related condition ovarian carcinoma